Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen to Split Stock

NEW YORK (GenomeWeb News) – Invitrogen announced yesterday that its board of directors has approved a two-for-one stock split.
 
The Carlsbad, Calif.-based firm said that shareholders of record on May 16 will receive on May 27 one additional share for each share held. The company had approximately 48.9 million shares of common stock outstanding as of the end of the first quarter on March 31.
 
Invitrogen’s shares closed at $93.57 in Wednesday trade on the Nasdaq.
 
Its stock has traded between $67.47 and $99.15 over the past 52 weeks, with a high of $99.15 reached on Dec. 10.
 
Last week, the firm reported that its first-quarter revenues rose 13.5 percent and its profit nearly doubled.
 

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.